D. Georgiopoulos

1 ta ish

Novartis (United Kingdom)

1. Economic evaluation of a single-pill triple antihypertensive therapy with valsartan, amlodipine, and hydrochlorothiazide against its dual components

   Panagiotis Stafylas, Georgia Kourlaba, M. Hatzikou +3

   Maqola20152 iqtibos

   ABIABI:AkademIndex/2026.other.451239